Targeted Combination Therapy for BRAF-Mutated Tumors
The invention is a combination therapy for treating tumors that express a mutated BRAF. The technology provides a synergistic effect by combining a specific antibody with an existing BRAF inhibitor, offering a novel solution for tumors that have developed resistance to current treatments.
Description
This invention details a new method for treating tumors using a combination of a therapeutically effective amount of an antibody that specifically binds to Glucose Regulated Protein (GRP) 94 and a BRAF inhibitor. This combination of agents has been shown to have a synergistic effect on tumors. The method is particularly useful for treating tumors where the cells express a mutated BRAF, such as in melanoma, and can be applied to subjects who have developed primary or secondary resistance to a BRAF inhibitor alone. Additionally, the treatment can decrease tumor metastasis.Applications
- Treatment of tumors expressing a mutated BRAF, such as melanoma.- Therapy for patients who have developed resistance to existing BRAF inhibitor treatments.
- Treatment of various cancers, including adenocarcinoma, small cell lung cancer, histiocytic lymphoma, and pancreatic and breast carcinoma.
- Combating tumor metastasis by decreasing the spread of cancerous cells.
- Application in treating specific squamous cell carcinomas of the head, neck, skin, lung, prostate, esophagus, vagina, and cervix.
Advantages
- A combination of agents provides a synergistic effect for tumor treatment.- Effective for tumors that express a mutated BRAF.
- Can be used to treat patients with primary or secondary resistance to a BRAF inhibitor.
- The method can decrease the metastasis of a tumor.
- Demonstrated to inhibit melanoma cell migration in vitro.